This promotional webinar series has been initiated and funded by Idorsia Pharmaceuticals UK Ltd and is intended for UK healthcare professionals only.

Nocturia in sleep disorders: management options in patients at risk of falls

Review the management options for nocturia in patients with sleep disorders, with particular consideration of the approaches to balancing treatment efficacy and fall risk in vulnerable patients. Dr Mercer will also discuss how QUVIVIQ® (daridorexant) can support the management of chronic insomnia in suitable patients.

This webinar will discuss QUVIVIQ (daridorexant), manufactured by Idorsia Pharmaceuticals.

1 CPD hour

Click here to view prescribing information and adverse event reporting information

QUVIVIQ (daridorexant) is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.1

1. QUVIVIQ Idorsia Pharmaceuticals Ltd, summary of product characteristics

Curious to see past webinars?

All past events in the Beyond Sleepless Nights series are available as on-demand learning modules to complete at your own pace, with CPD hours available.

Discover more on MIMS Learning